Moreover, observational and mechanistic studies have linked higher systemic inflammation (e.g., elevated IL-6, CRP) with worse outcomes in pneumonia (15–17), and randomized trials suggest that the largest clinical gains from adjunctive corticosteroids occur in patients with a pronounced inflammatory response (8, 13). This evidence concerns the gene CRP and susceptibility to pneumonia measurement.